We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Medical Imaging Health IT Point of Care Business Focus

COVID-19 Patients Have Low Oxygen Levels Due to Damaged Blood Cells, Finds Study

By HospiMedica International staff writers
Posted on 08 Jul 2020
Illustration
Illustration
A report by Reuters has stated that the damage caused by the coronavirus to the membranes of red blood cells that carry oxygen could explain why several COVID-19 patients have alarmingly low oxygen levels.

Researchers from the University of Colorado Anschutz Medical Campus (Aurora, CO, USA) and Columbia University (New York, NY, USA) conducted a study combining state-of-the-art metabolomics, proteomics, and lipidomics approaches to investigate the impact of COVID-19 on RBCs from 23 healthy subjects and 29 molecularly-diagnosed COVID-19 patients. The researchers found that the RBCs from COVID-19 patients had increased levels of glycolytic intermediates, accompanied by oxidation and fragmentation of ankyrin, spectrin beta, and the N-terminal cytosolic domain of band 3 (AE1). Significantly altered lipid metabolism was also observed, especially short and medium chain saturated fatty acids, acyl-carnitines, and sphingolipids. However, there were no alterations of clinical hematological parameters, such as RBC count, hematocrit, and mean corpuscular hemoglobin concentration, with only minor increases in mean corpuscular volume.

According to the researchers, the findings suggested a significant impact of SARS-CoV-2 infection on RBC structural membrane homeostasis at the protein and lipid levels. The increases in RBC glycolytic metabolites were consistent with a theoretically improved capacity of hemoglobin to off-load oxygen as a function of allosteric modulation by high-energy phosphate compounds, perhaps to counteract COVID-19-induced hypoxia. Conversely, because the N-terminus of AE1 stabilizes deoxyhemoglobin and finely tunes oxygen off-loading, RBCs from COVID-19 patients may be incapable of responding to environmental variations in hemoglobin oxygen saturation when traveling from the lungs to peripheral capillaries and, as such, may have a compromised capacity to transport and deliver oxygen.

"Since red cells circulate for up to 120 days, this could also help explain why it can take months to recover from the virus ... until enough new red cells without this damage are made and circulate," senior researcher Angelo D'Alessandro of the University of Colorado Anschutz Medical Campus told Reuters.

Related Links:
University of Colorado Anschutz Medical Campus
Columbia University


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Rapid Sepsis Test
SeptiCyte RAPID
Wound Irrigation Solution
Prontosan®

Channels

Surgical Techniques

view channel
Illustration of the Hēlo Thrombectomy System device (Photo courtesty of Endovascular Engineering)

FDA-Cleared Thrombectomy System Removes Pulmonary Embolism Clots

Pulmonary embolism occurs when blood clots travel to the lungs and block blood flow, potentially requiring urgent endovascular intervention to prevent death. Catheter-based clot removal can be challenging,... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more